Medication info
Pregast Capsules 75 mg (Pregabalin)

Pregast Capsules 75 mg (Pregabalin)

Prescription medicationHard capsule
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Bukwang Pharmaceutical Co., Ltd.
Appearance
Hard capsules with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201603681 · Approved 2016.06.21 · Insurance code 642204110

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who uses it
Adults · Children
Adult dosage
The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see 5. Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see 4. Discontinuation of treatment). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses greater than 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys as unchanged drug. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under Administration. b: The additional dose refers to a supplemental dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Bukwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia.
View approved original text

This medication is used in adults to relieve pain caused by peripheral and central neuropathic conditions. It is also used as an adjunctive treatment for patients with epilepsy who have partial seizures, applicable in both cases with or without secondary generalization. Additionally, it helps relieve pain from fibromyalgia. In summary, it is used for neuropathic pain, adjunctive treatment for partial seizures in epilepsy, and treatment of fibromyalgia.

Dosage and Administration

Adult dosage

The total daily dose of this medicine, as pregabalin, is administered orally in 2 divided doses, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see 5. Patients with renal impairment). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see 4. Discontinuation of treatment). 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on individual patient response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The starting dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. Given the dose-dependent adverse reactions, doses greater than 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys as unchanged drug. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose according to renal function, an additional supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Administration Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose administered in 3 divided doses BID = Total daily dose administered in 2 divided doses QD = Administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under Administration. b: The additional dose refers to a supplemental dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This drug is used in the treatment of epilepsy, and there may be an increased risk of suicidal thoughts or behaviors during its use, so patients and guardians should closely monitor for these symptoms. Do not take this medication if there is hypersensitivity to this drug or any genetic issues like lactose intolerance. Patients with diabetes should be cautious as weight gain from this drug may require adjustment of blood glucose control medications. If allergic reactions such as angioedema occur, stop taking the drug immediately. Elderly patients should be cautious as the risk of falls may increase due to dizziness or drowsiness. This drug can cause visual disturbances such as blurred vision, and symptoms may improve after discontinuation of the medication. Withdrawal symptoms such as insomnia, headaches, nausea, and anxiety may occur upon sudden discontinuation, so abrupt cessation should be avoided. There is a risk of drug abuse; thus, patients with a history of mental health issues or substance abuse should be particularly careful. Patients with impaired kidney function need dosage adjustments, and those with severe heart disease should take this drug with caution. Co-administration with opioid analgesics may lead to exacerbated central nervous system depression, so caution is required. In early pregnancy, there is a risk of fetal malformations, so women who are pregnant or planning to become pregnant must consult a physician before taking this medication and must use effective contraceptive methods during treatment. Breastfeeding mothers should decide whether to discontinue nursing or the medication, as this drug is excreted in breast milk. Before driving or operating machinery, check for symptoms of dizziness or drowsiness caused by this drug. In cases of overdose, changes in mental status, drowsiness, and seizures may occur, and immediate medical attention is necessary, with possible need for hemodialysis. This medication should be stored out of reach of children, and transferring to another container is not advisable for maintaining quality. If severe allergic reactions such as skin rash, fever, or difficulty breathing occur during treatment, stop taking the drug immediately and consult medical personnel.

Side effects

  • suicidal ideation
  • suicidal behavior
  • depression
  • abnormal mood and behavior changes
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 204 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like illness
  • restlessness
  • suicidal thoughts
  • pain
  • seizures
  • excessive sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • decreased respiratory function
  • respiratory diseases
  • neurological disorders
  • kidney impairment
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • spatial disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • sexual hyperesthesia
  • agitation
  • mood swings
  • emotional dysphoria
  • emotional elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • uncontrollable behavior
  • apathy
  • ataxia
  • abnormal motor coordination
  • balance disorders
  • amnesia
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory abnormalities
  • sensory deficits
  • sedation
  • hypersomnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • tonic-clonic seizures
  • decreased reflexes
  • motor disturbances
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremors
  • syncope
  • confusion
  • hypokinesia
  • olfactory disturbances
  • loss of taste
  • writing difficulties
  • blurred vision
  • diplopia
  • indirect vision loss
  • visual disturbances
  • visual field defects
  • photophobia
  • dry eyes
  • eye swelling
  • decreased vision
  • eye pain
  • eye fatigue
  • increased tear production
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • visual brightness
  • vertigo
  • auditory hypersensitivity
  • first-degree atrioventricular block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory deficit
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweat
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urine output
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling drunk
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • affective disorders
  • drowsiness
  • confusion state
  • depression
  • agitation
  • restlessness
  • worsening of seizures
  • sleep disorders
  • blood in stool
  • tinnitus
  • gastrointestinal disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to keep the storage temperature between 15 and 30 degrees Celsius to maintain the medication's effectiveness for a longer period.

Appearance and packaging

Appearance

Hard capsules with a reddish-brown upper part and a white lower part containing white powder that is white or light yellow.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.